The Tennessee Tech student had been taking the drug for about six months when she suddenly passed out in the shower. Her roommate called 911, and when Leah briefly regained consciousness, her roommate got her mother, Traci, on the phone. “Leah told me that she was scared, and that she was tingling all over,” Traci tells WREG-TV. “I told her it was going to be OK, that me and daddy was coming.”

But they arrived too late. Leah died less than an hour after she collapsed. Doctors say what killed her was a blood clot in her lung, also known as a pulmonary embolism. “How does this happen to a healthy 20-year-old lady?” Traci asks. The answer may be in the birth control pill she was taking.

The diuretic drospirenone that is in Yaz can cause an increase in potassium levels in the blood, which can lead to hyperkalemia, a condition that causes heart rhythm disturbances that can cause blood clots that can trigger cardiac death or pulmonary embolism or strokes. Diuretics also can cause significant problems with the gallbladder, leading to gallbladder removal.

The Mayfields have joined at least 50 other women injured by Yaz and filed a lawsuit against Bayer. The lawsuit alleges that the drug maker ignored the increased risks of Yaz and kept it on the market to enjoy mounting profits. Now Traci wants to warn others of the dangers of Yaz.

“(Leah) didn’t have to die,” Traci says. “She didn’t have to die because of a pill.

SOURCE: Yaz Lawsuit › Mother warns others of the dangers of Yaz

But a group of 50 women in Indianapolis say Bayer is wrong. They are the latest victims to file lawsuits against the drug company, alleging the new formulation of birth control pills caused heart attacks, strokes, blood clots and other health problems.

Yaz and Yasmin, also known by the generic brand Ocella, is as the company’s ads claim – different than other birth control pills. Bayer’s top-selling contraceptive drugs contain ethinyl estradiol plus drospirenone. Drospirenone is a diuretic, which the lawsuits argue can lead to dangerously high levels of potassium, which can lead to hyperkalema. Hyperkalema is a condition that can cause heart rhythm disturbances, which can trigger blood clots and sudden cardiac death or pulmonary embolism or strokes.

The lawsuits allege that Yaz and Yasmin are more aggressive than other oral contraceptives and have left plaintiffs with blood clots and pulmonary embolisms in their legs and lungs. Many had to have their gallbladders removed. Others suffered strokes.

Yet, Bayer, which reaped more than $600 million in sales in 2008, says it is not at fault. “The complaints we have reviewed so far pertain to side effects that are warned about in the labeling of all oral contraceptives, including ours,” according to a statement from Bayer spokeswoman Rose Talarie.

Sources:
UPI
Fox59
Indy Star

SOURCE: Yaz Lawsuit › Bayer claims no fault in Yaz, Yasmin injuries, deaths

All of the lawsuits allege that Yaz and Yasmin caused adverse events attributable to the ingredient drospirenone (DRSP), which has been linked to blood clots, strokes, heart attacks, gall bladder disease, deep vein thrombosis, pulmonary embolism, and other serious reactions, including sudden death. The suits assert that Bayer knew about the risks but failed to disclose them to consumers while at the same time aggressively marketing the drug.

Last year, the U.S. Food and Drug Administration warned Bayer that its television advertisements for Yaz were misleading and failed to disclose all of the drug’s risks.

Traditional birth control drugs do not contain DRSP, which is a new type of progestin that influences the body’s natural ability to balance salt and water, which could adversely lead to elevated potassium levels. Excessive potassium levels in the body may trigger fatal cardiac arrhythmia and other serious health problems.

The FDA received more than 50 reports of deaths linked to Yaz and Yasmin between 2004 and 2008. The fatalities involved heart attacks, pulmonary embolisms, and strokes. Excessive blood potassium levels were found in many of the cases.

A U.S. Judicial Panel on Multidistrict Litigation has scheduled a hearing for September 24 to decide if the Yaz and Yasmin lawsuits currently pending in federal courts are similar enough to be consolidated into an MDL (multi-district litigation).

SOURCE: Yaz Lawsuit › Yaz lawsuits consolidated in Pennsylvania